JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120257

Philanthotoxin-7,4 (PhTx-74), GluA1/GluA2 (formerly GluR1/2) inhibitor

Be the first to review this product! Submit a review

|

(3 Publications)

MW 507.5 Da, Purity >98%. A subtype-selective, use-dependent inhibitor of native AMPA receptors. Inhibits GluA1/A2 (formerly GluR1/2), with little activity at GluA2/A3 (formerly GluR2/3).
1 Images
Chemical Structure - Philanthotoxin-7,4 (PhTx-74), GluA1/GluA2 (formerly GluR1/2) inhibitor (AB120257)
  • Chemical Structure

Lab

Chemical Structure - Philanthotoxin-7,4 (PhTx-74), GluA1/GluA2 (formerly GluR1/2) inhibitor (AB120257)

2D chemical structure image of ab120257, Philanthotoxin-7,4 (PhTx-74), GluA1/GluA2 (formerly GluR1/2) inhibitor

Key facts

CAS number

401601-12-5

Purity

>98%

Form

Solid

form

Molecular weight

507.5 Da

Molecular formula

C<sub>2</sub><sub>4</sub>H<sub>4</sub><sub>4</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>3</sub>

PubChem

46213501

Nature

Synthetic

Biochemical name

Philanthotoxin 74

Biological description

A subtype-selective, use-dependent inhibitor of native AMPA receptors. Inhibits GluA1/A2 (formerly GluR1/2), with little activity at GluA2/A3 (formerly GluR2/3)

Canonical smiles

CCCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NCCCCCCCNCCCCN.Cl.Cl

Isomeric smiles

CCCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCCCCCCCNCCCCN.Cl.Cl

InChi

InChI=1S/C24H42N4O3.2ClH/c1-2-10-23(30)28-22(19-20-11-13-21(29)14-12-20)24(31)27-18-8-5-3-4-7-16-26-17-9-6-15-25;;/h11-14,22,26,29H,2-10,15-19,25H2,1H3,(H,27,31)(H,28,30);2*1H/t22-;;/m0../s1

InChiKey

HWTJQQMIKVJWLH-IKXQUJFKSA-N

IUPAC Name

N-[(2S)-1-[7-(4-aminobutylamino)heptylamino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]butanamide;dihydrochloride

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Glutamate Receptor 1 (AMPA subtype) also known as GluR1 is a subunit of the AMPA receptor complex which mediates fast synaptic transmission in the central nervous system. It is an ionotropic receptor for glutamate functioning by opening ion channels to allow the flow of Na+ and Ca2+ ions across the cell membrane contributing to excitatory neurotransmission. The GluR1 subunit has a molecular mass of approximately 100 kDa. This receptor is commonly expressed in the brain regions such as the hippocampus and the cerebral cortex playing an important role in synaptic plasticity and memory formation.
Biological function summary

The GluR1 subunit is an essential component of the AMPA receptor complex which typically forms as a tetramer. This complex modulates synaptic strength and plasticity processes critical for learning and memory. The activity of AMPA receptors including those containing GluR1 is regulated by several auxiliary proteins and is essential for post-synaptic responses. The GluR1 subunit also interacts with other proteins such as TARPs which modulate its trafficking and channel properties.

Pathways

The GluR1-containing AMPA receptors participate significantly in the glutamatergic signaling pathway which is vital for fast excitatory synaptic transmission in the brain. This pathway also involves the NMDA receptors which work together with AMPA receptors to regulate synaptic plasticity and neuronal communication. Additionally the GluR1 interacts within the long-term potentiation (LTP) pathway contributing to the strengthening of synapses an essential mechanism underlying learning and memory.

Dysfunction in GluR1 and associated AMPA receptors has been implicated in conditions like Alzheimer's disease and epilepsy. Alzheimer's disease exhibits decreased synaptic transmission and plasticity linked to impaired GluR1 function and its interactions with NMDA receptors. In epilepsy abnormal GluR1 activity may contribute to heightened neuronal excitability and seizure propagation. Targeting GluR1 or associated pathways offers potential for therapeutic interventions in these disorders possibly through drugs such as memantine and NBQX which modulate receptor activity.

Product protocols

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Acta neuropathologica communications 12:40 PubMed38481314

2024

DNA hypomethylator phenotype reprograms glutamatergic network in receptor tyrosine kinase gene-mutated glioblastoma.

Applications

Unspecified application

Species

Unspecified reactive species

Mio Harachi,Kenta Masui,Erika Shimizu,Kumiko Murakami,Hiromi Onizuka,Yoshihiro Muragaki,Takakazu Kawamata,Hisako Nakayama,Mariko Miyata,Takashi Komori,Webster K Cavenee,Paul S Mischel,Atsushi Kurata,Noriyuki Shibata

Neuroscience bulletin 37:669-683 PubMed33779892

2021

A Role for Transmembrane Protein 16C/Slack Impairment in Excitatory Nociceptive Synaptic Plasticity in the Pathogenesis of Remifentanil-induced Hyperalgesia in Rats.

Applications

Unspecified application

Species

Unspecified reactive species

Yize Li,Linlin Zhang,Jing Li,Chunyan Wang,Yi Chen,Yuan Yuan,Keliang Xie,Guolin Wang,Yonghao Yu

Cell death discovery 7:11 PubMed33446662

2021

Acetylation-dependent glutamate receptor GluR signalosome formation for STAT3 activation in both transcriptional and metabolism regulation.

Applications

Unspecified application

Species

Unspecified reactive species

Xiang-Rong Li,Xiaju Cheng,Jia Sun,Yan S Xu,Nannan Chen,Yimei Hao,Chao Huang,Y Eugene Chin
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com